Beijing Strong Biotechnologies Inc
Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. The company offers biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activ… Read more
Beijing Strong Biotechnologies Inc (300406) - Total Assets
Latest total assets as of September 2025: CN¥5.30 Billion CNY
Based on the latest financial reports, Beijing Strong Biotechnologies Inc (300406) holds total assets worth CN¥5.30 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Beijing Strong Biotechnologies Inc - Total Assets Trend (2011–2024)
This chart illustrates how Beijing Strong Biotechnologies Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Beijing Strong Biotechnologies Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Strong Biotechnologies Inc's total assets of CN¥5.30 Billion consist of 46.3% current assets and 53.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.7% |
| Accounts Receivable | CN¥1.13 Billion | 20.2% |
| Inventory | CN¥220.68 Million | 4.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥57.08 Million | 1.0% |
| Goodwill | CN¥1.67 Billion | 30.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Beijing Strong Biotechnologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Strong Biotechnologies Inc's current assets represent 46.3% of total assets in 2024, a decrease from 78.0% in 2011.
- Cash Position: Cash and equivalents constituted 18.7% of total assets in 2024, down from 26.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 1.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 30.0% of total assets.
Beijing Strong Biotechnologies Inc Competitors by Total Assets
Key competitors of Beijing Strong Biotechnologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Beijing Strong Biotechnologies Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Beijing Strong Biotechnologies Inc generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Beijing Strong Biotechnologies Inc generates $9.55 in net profit.
Beijing Strong Biotechnologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.66 | 9.03 | 7.30 |
| Quick Ratio | 10.63 | 8.21 | 6.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.22 Billion | CN¥ 2.31 Billion | CN¥ 1.53 Billion |
Beijing Strong Biotechnologies Inc - Advanced Valuation Insights
This section examines the relationship between Beijing Strong Biotechnologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.84 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 7.7% |
| Total Assets | CN¥5.57 Billion |
| Market Capitalization | $317.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Strong Biotechnologies Inc's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing Strong Biotechnologies Inc's assets grew by 7.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing Strong Biotechnologies Inc (2011–2024)
The table below shows the annual total assets of Beijing Strong Biotechnologies Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.57 Billion | +7.71% |
| 2023-12-31 | CN¥5.18 Billion | +12.20% |
| 2022-12-31 | CN¥4.61 Billion | +6.79% |
| 2021-12-31 | CN¥4.32 Billion | +8.98% |
| 2020-12-31 | CN¥3.96 Billion | +84.01% |
| 2019-12-31 | CN¥2.15 Billion | +15.51% |
| 2018-12-31 | CN¥1.86 Billion | +4.84% |
| 2017-12-31 | CN¥1.78 Billion | +20.91% |
| 2016-12-31 | CN¥1.47 Billion | +16.59% |
| 2015-12-31 | CN¥1.26 Billion | +20.80% |
| 2014-12-31 | CN¥1.04 Billion | +100.52% |
| 2013-12-31 | CN¥520.88 Million | +20.44% |
| 2012-12-31 | CN¥432.48 Million | +36.56% |
| 2011-12-31 | CN¥316.70 Million | -- |